改善病情抗风湿药对类风湿关节炎患者血脂谱的影响

被引：13

作者：

赵凌杰

张蓓蓓

机构：

[1] 南京总医院中西医结合科

来源：

中国免疫学杂志 | 2018年 / 34卷 / 04期

关键词：

类风湿关节炎; 改变病情抗风湿药; 血脂谱;

D O I：

暂无

中图分类号：

R593.22 [类风湿性关节炎];

学科分类号：

100201 [内科学];

摘要：

类风湿关节炎(RA)患者心血管风险明显高于正常人群,血脂代谢异常与之密切相关。作为RA治疗的基石,改变病情抗风湿药(DMARDs)对血脂水平的影响仍存在很大争议,部分药物可能促进动脉粥样硬化。本文总结分析了DMARDs对RA患者血脂谱的影响,提示抗风湿药的心血管安全性应引起重视。

引用

页码：636 / 641

页数：6

共 16 条

[1]

Relationship of baseline HDL subclasses; small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.[J].John J. Albers;April Slee;Jerome L. Fleg;Kevin D. O’Brien;Santica M. Marcovina.Atherosclerosis.2016,

[2]

Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial [J].

Charles-Schoeman, Christina ;

Wang, Xiaoyan ;

Lee, Yuen Yin ;

Shahbazian, Ani ;

Navarro-Millan, Iris ;

Yang, Shuo ;

Chen, Lang ;

Cofield, Stacey S. ;

Moreland, Larry W. ;

O'Dell, James ;

Bathon, Joan M. ;

Paulus, Harold ;

Bridges, S. Louis, Jr. ;

Curtis, Jeffrey R. .

ARTHRITIS & RHEUMATOLOGY, 2016, 68 (03) :577-586

[3]

Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib<link href="#art38974-note-0001 #art38974-note-0002"/>.[J].Christina Charles‐Schoeman;Roy Fleischmann;Jean Davignon;Howard Schwartz;Scott M. Turner;Carine Beysen;Mark Milad;Marc K. Hellerstein;Zhen Luo;Irina V. Kaplan;Richard Riese;Andrea Zuckerman;Iain B. McInnes.Arthritis & Rheumatology.2015, 3

[4]

HDL Particle Size Is a Critical Determinant of ABCA1-Mediated Macrophage Cellular Cholesterol Export [J].

Du, Xian-Ming ;

Kim, Mi-Jurng ;

Hou, Liming ;

Le Goff, Wilfried ;

Chapman, M. John ;

Van Eck, Miranda ;

Curtiss, Linda K. ;

Burnett, John R. ;

Cartland, Sian P. ;

Quinn, Carmel M. ;

Kockx, Maaike ;

Kontush, Anatol ;

Rye, Kerry-Anne ;

Kritharides, Leonard ;

Jessup, Wendy .

CIRCULATION RESEARCH, 2015, 116 (07) :1133-1142

[5]

Editorial: Inflammation; Disease‐Modifying Antirheumatic Drugs; Lipids; and Cardiovascular Risk in Rheumatoid Arthritis.[J].Katherine P. Liao;Daniel H. Solomon.Arthritis & Rheumatology.2015, 2

[6]

Lipid Profile Changes in Patients With Chronic Inflammatory Arthritis Treated With Biologic Agents and Tofacitinib in Randomized Clinical Trials A Systematic Review and Meta-Analysis [J].

Souto, Alejandro ;

Salgado, Eva ;

Ramon Maneiro, Jose ;

Mera, Antonio ;

Carmona, Loreto ;

Gomez-Reino, Juan J. .

ARTHRITIS & RHEUMATOLOGY, 2015, 67 (01) :117-127

[7]

Associations of Hydroxychloroquine Use With Lipid Profiles in Rheumatoid Arthritis: Pharmacologic Implications [J].

Kerr, Gail ;

Aujero, Mireille ;

Richards, John ;

Sayles, Harlan ;

Davis, Lisa ;

Cannon, Grant ;

Caplan, Liron ;

Michaud, Kaleb ;

Mikuls, Ted .

ARTHRITIS CARE & RESEARCH, 2014, 66 (11) :1619-1626

[8]

Tumor Necrosis Factor α Inhibitor Use and Decreased Risk for Incident Coronary Events in Rheumatoid Arthritis [J].

Bili, Androniki ;

Tang, Xiaoqin ;

Pranesh, Shruthi ;

Bozaite, Rasa ;

Morris, Stephanie J. ;

Antohe, Jana L. ;

Kirchner, H. Lester ;

Wasko, Mary Chester M. .

ARTHRITIS CARE & RESEARCH, 2014, 66 (03) :355-363

[9]

Statins Do Not Influence Long-Term Rituximab Clinical Efficiency in Rheumatoid Arthritis Patients.[J].Diana Mazilu;Tania Gudu;Ruxandra Ionescu;Daniela Opris;Shigeru Kotake.BioMed Research International.2014,

[10]

Cardiovascular risk in rheumatoid arthritis: How to lower the risk? [J].

van Breukelen-van der Stoep, D. F. ;

Klop, B. ;

van Zeben, D. ;

Hazes, J. M. W. ;

Cabezas, M. Castro .

ATHEROSCLEROSIS, 2013, 231 (01) :163-172

← 1 2 →